2-5 As Activity in Serum and Peripheral Blood Mononuclear Cells for Chronic Active Hepatitis C and the Relationship to Clinical Outcome of Interferon Therapy

Japanese Journal of Clinical Immunology

Volumn 20, Issue 5, 1997, Pages 428-436

  Toda, Kyoko ^a   Kumagai, Naoki ^a   Iwabuchi, Naoto ^a   Suzuki, Tatsuo ^a   Saito, Hidetsugu ^b   Morizane, Toshio ^c   Hibi, Toshifumi ^b   Ishii, Hiromasa ^b   Tsuchimoto, Kanji ^a  

^a KITASATO INSTITUTE HOSPITAL   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c KANAGAWA DENTAL COLLEGE   (Japan)

Author keywords

2 5 Oligoadenylate Synthetase (2 5 AS); Chronic hepatitis C; Interferon; Peripheral blood mononuclear cells

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; ANTIVIRUS AGENT; BIOLOGICAL MARKER; INTERFERON;

ARTICLE; BLOOD; CELL CULTURE; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MONONUCLEAR CELL; TREATMENT OUTCOME;

2',5'-OLIGOADENYLATE SYNTHETASE; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CELLS, CULTURED; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LEUKOCYTES, MONONUCLEAR; TREATMENT OUTCOME;

EID: 0031244049     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.20.428     Document Type: Article

References (16)

1. Greenberg, H.B., Pollard, R.B., Lutwick, L.I., et al.: Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N. Engl. J. Med., 295: 517–522, 1976.
2. Pollard, R.B., et al.: Effect of vidarabine on chronic hepatitis B virus infection. JAMA, 239: 1648–1650, 1978.
3. R.G., Chadwick, et al., HBs Ag-positive chronic liver disease: Inhibition of DNA polymerase activity by vidarabine, Brit. Med. J., (1978), 2, 531-533
4. Nilsen, T.W., Baglioni, C.: Mechanism for discrimination between viral and host mRNA in interferon-treated cells. Proc. Natl. Acad. Sci. USA, 76: 2600–2604, 1979.
5. Sugawara, T., et al.: Activities of 2’-5’-oligoadenylate synthetase in peripheral blood mononuclear cells of patients with viral hepatitis and chronic type B hepatitis during interferon therapy. Jap. J. Med., 25: 144–148, 1986.
6. Nishiguchi, S., et al.: Relationship of the effects of interferon on chronic hepatitis B and the induction of 2’-5’-oligoadenylate synthetase. Hepatology, 10: 29–33, 1989.
7. Hoofnagle, J.H., Mullen, K.D., Jones, D.B., et al.: Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. N. Engl. J. Med., 315: 1575–1578, 1986.
8. Thomson, B.J., Doran, M., Lever, A.M.L., et al.: Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy. Lancet, 1: 539–541, 1987.
9. Choo, Q.L., et al.: Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science, 244: 359, 1989.
10. Kuo, G., et al.: An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science, 244: 362–364, 1989.
11. G.L., Davis, et al., Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial, N. Engl. J. Med., (1989), 321, 1501-1506
12. A.M., Di Biscegle, et al., Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial, N. Engl. J. Med., (1989), 321, 1506-1510
13. Okamoto, H., et al.: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol., 73: 673–679, 1992.
14. Okamoto, H., et al.: Characterization of the genomic sequence of type V (or 3 a) hepatitis C virus isolates and PCR primers for specific detection. J. Gen. Virol., 74: 2835–3390, 1993.
15. Kumagai, N., et al.: Assessment of histological features and outcome of interferon therapy in chronic hepatitis, c.J. Gastroenterol., 31: 69–74, 1996.
16. Tsubota, A., et al.: Factors predictive of response to interferon-α therapy in hepatitis c virus infection. Hepatology, 19: 1088–1094, 1994.